APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells.
Saved in:
| Title: | APR-246 overcomes resistance to cisplatin and doxorubicin in ovarian cancer cells. |
|---|---|
| Authors: | Mohell N; Aprea AB, Solna, Sweden., Alfredsson J; Aprea AB, Solna, Sweden., Fransson Å; Aprea AB, Solna, Sweden., Uustalu M; Aprea AB, Solna, Sweden., Byström S; Aprea AB, Solna, Sweden., Gullbo J; 1] Clinical Pharmacology, Department of Medical Sciences, Uppsala University, Uppsala, Sweden [2] Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden., Hallberg A; Department of Medicinal Chemistry, BMC, Uppsala University, Uppsala Sweden., Bykov VJ; Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden., Björklund U; Aprea AB, Solna, Sweden., Wiman KG; Department of Oncology-Pathology, Cancer Center Karolinska, Karolinska Institutet, Stockholm, Sweden. |
| Source: | Cell death & disease [Cell Death Dis] 2015 Jun 18; Vol. 6, pp. e1794. Date of Electronic Publication: 2015 Jun 18. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101524092 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-4889 (Electronic) NLM ISO Abbreviation: Cell Death Dis Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
